Effects of Immulina on Immune Measures

Overview

This small, randomized, double blind, placebo controlled pilot study is aimed at determining the effects of oral Immulina dietary supplementation on specific immune biomarkers in the blood.

Full Title of Study: “Effects of Immulina Dietary Supplementation on Innate and Adaptive Immune Measures in Normal Human Volunteers”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Supportive Care
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: December 2020

Detailed Description

This small, randomized, double blind, placebo controlled pilot study is aimed at determining the effects of four weeks of daily Immulina dietary supplementation (800 mg/day) versus four weeks of daily placebo on natural killer (NK) cell numbers and/or natural killer (NK) cell activity in human peripheral blood mononuclear cells collected from human research participants who meet the trial's inclusion/exclusion criteria.

Interventions

  • Dietary Supplement: Immulina Dietary Supplementation
    • Immulina Dietary Supplementation is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.

Arms, Groups and Cohorts

  • Experimental: Immulina Dietary Supplementation
    • Immulina Dietary Supplementation – 200 mg capsules; 800 mg/day; 2 (200 mg) capsules given by mouth in the morning and 2 (200 mg) capsules given by mouth in the evening for 4 weeks duration
  • Placebo Comparator: Placebo
    • Placebo – inert capsules; 2 capsules given by mouth in the morning and 2 capsules given by mouth in the evening for 4 weeks duration

Clinical Trial Outcome Measures

Primary Measures

  • Natural Killer (NK) cell count
    • Time Frame: 4 weeks
    • Differences in NK cell counts from baseline to 4 weeks

Secondary Measures

  • Natural Killer (NK) cell cytotoxic activity
    • Time Frame: 4 weeks
    • Differences in NK cell cytotoxic activity from baseline to 4 weeks
  • Cytokine profiles
    • Time Frame: 4 weeks
    • Differences in in-Vitro peripheral blood mononuclear cell (PBMC) culture supernatants’ cytokine profiles from baseline to 4 weeks (IFN-α, IFN-γ, IL-1β, IL-2, IL-4, IL-6, Il-10, IL-12, Il-15 and TNFα)
  • Immune cell populations
    • Time Frame: 4 weeks
    • Differences in immune cell populations in PBMC from baseline to 4 weeks.

Participating in This Clinical Trial

Inclusion Criteria

  • Normal, generally healthy adults between ages 18-64 and who may or may not have a controlled disease(s). Examples of controlled diseases are controlled Type-2 diabetes mellitus, controlled hypertension, controlled allergic rhinitis, etc.

Exclusion Criteria

  • Individuals with specific disease entities, which, in the opinion of the Principal Investigator, could reasonably be assumed to have dysfunctional immune function as a component of their illness. These include HIV, AIDS, uncontrolled asthma, uncontrolled eczema, uncontrolled allergic rhinitis, uncontrolled urticaria, rheumatoid arthritis, lupus, inflammatory bowel disease, multiple sclerosis, Type-1 diabetes mellitus, Guillain-Barre syndrome, psoriasis, Grave's disease, Hashimoto's thyroiditis, myasthenia gravis or vasculitis.
  • Individuals taking specific dietary supplements including probiotic, microalgae or beta glucan containing dietary supplements, fermented food products (such as yogurt, bean curd, etc.). If the potential participants reports usage of any of these products, they will be asked if they would be willing to withhold products for 30 days and then be re-screened for inclusion/exclusion criteria.
  • Individuals who are unwilling to refrain for the duration of the trial from taking the specific dietary supplements and fermented food products including probiotic, microalgae or beta glucan containing dietary supplements, fermented food products (such as yogurt, bean curd, etc.).
  • Pregnant females (because baseline immune responses, are altered by pregnancy)
  • Individuals unable to speak, understand and read English

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 64 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Mississippi Medical Center
  • Provider of Information About this Clinical Study
    • Principal Investigator: Gailen D. Marshall Jr., MD PhD, The R. Faser Triplett, Sr., MD Chair of Allergy and Immunology, Professor of Medicine, Pediatrics, Pathology and Population Science – University of Mississippi Medical Center
  • Overall Official(s)
    • Gailen D Marshall, Jr., MD, PhD, Principal Investigator, Study Principal Investigator

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.